Introduction: Eczema, also known as atopic dermatitis, is a common skin condition characterized by dry, itchy skin. While ...

FDA approves Elanco's once-daily oral treatment, Zenrelia, for controlling itching in dogs with allergic and atopic ...

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

The canine atopic dermatitis treatment market is set to experience notable growth, with an expected increase from USD ...

Pharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD) market is projected ...

Elanco Animal Health Inc. (ELAN) announced the U.S. Food and Drug Administration has approved Zenrelia, a convenient once-daily oral ...

Mycosis fungoid (MF), the most prevalent cutaneous T-cell lymphoma, frequently remains undiagnosed in its early stages due to ...

The oral drug, Zenrelia, is to control pruritus, or itching, associated with allergic dermatitis and control of atopic ...

The FDA announced earlier today that ilunocitinib tablets (Zenrelia; Elanco) has received its approval. The latest drug from ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

A new single-dose autoinjector presentation of Adbry is now available for use in the treatment of moderate to severe atopic dermatitis.